| 產(chǎn)品編號(hào) | bs-17611R |
| 英文名稱 | CCDC49 Rabbit pAb |
| 中文名稱 | 卷曲螺旋結(jié)構(gòu)域蛋白49抗體 |
| 別 名 | Coiled-coil domain-containing protein 49; CWC25_HUMAN; Pre-mRNA-splicing factor CWC25 homolog. |
| 研究領(lǐng)域 | 細(xì)胞生物 信號(hào)轉(zhuǎn)導(dǎo) |
| 抗體來(lái)源 | Rabbit |
| 克隆類型 | Polyclonal |
| 克 隆 號(hào) | |
| 交叉反應(yīng) | Mouse,Rat (predicted: Human,Rabbit,Pig,Sheep,Cow,Horse) |
| 產(chǎn)品應(yīng)用 | WB=1:500-2000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 50 kDa |
| 檢測(cè)分子量 | |
| 細(xì)胞定位 | 細(xì)胞膜 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human CCDC49: 351-425/425 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
Spliceosomes are large ribonucleoproteins that remove introns from nuclear pre-mRNA in a two-step reaction. CCDC49 is a 425 amino acid protein that is involved in the catalytic steps of splicing in Saccharomyces cerevisiae. CCDC49 associates with a component of the Prp19-associated complex, CEF1, which is involved in spliceosome activation. It is likely that CCDC49 facilitates juxtaposition of the 5’ splice site and branch point during the final step in the first catalytic reaction. There are two isoforms of CCDC49 that are produced as a result of alternative splicing events. Similarity: Belongs to the CWC25 family. SWISS: Q6ZUS6 Gene ID: 91050 Database links: Entrez Gene: 91050 Human Entrez Gene: 100503884 Mouse SwissProt: Q6ZUS6 Human Unigene: 106432 Human Unigene: 332379 Mouse |
| 產(chǎn)品圖片 |
25 ug total protein per lane of various lysates (see on figure) probed with CCDC49 polyclonal antibody, unconjugated (bs-17611R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.
|
